linjc16/ctgov huggingface dataset:
SS-GCC1- Screening Study of Genetic Changes in Colorectal Cancer

Study Overview
=================
Brief Summary
-----------------
the principal research objective is to form a database of tissue samples from patients with colorectal (bowel) cancer. The tissue samples that will be used for this research will have already been taken for diagnostic or therapeutic reasons. We will also be asking for consent for a research blood sample. The database will be used to improve our understanding of the molecular genetics and gene expression patterns in colorectal cancer.

Detailed Description
-----------------
All patients at the Royal Marsden with a diagnosis of colorectal cancer will be eligible to enter this study. This will include patients both with early and advanced disease, provided they give informed consent. They will give written consent to participate, to include consent for analysis of existing tumour tissue and consent for collection of demographic and clinicopathological data relating to their case and its future outcome, and consent for a blood sample to be taken for research purposes. Additionally, old samples of material surplus to clinical requirements may be collected without specific consent if there is no possibility that it would affect the patient's interest (eg the patient has died).

Official Title
-----------------
SS-GCC1- Screening Study of Genetic Changes in Colorectal Cancer

Conditions
-----------------
Colorectal Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adults who have a terminal illness 18 and over confirmed diagnosis of colorectal carcinoma ability to give informed consent paraffin embedded histological material available for analysis Exclusion Criteria: medical or psychiatric conditions impairing ability to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No treatment<br>confirmed diagnosis of colorectal carcinoma | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the primary endpoint is the identification of cases with evidence of loss of the product of one of the four main MMR genes on tumour histology. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Secondary outcome measure is the survival and response to treatment of the identified cases. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
colorectal, cancer, gene expression, biomarker, genomic mismatch repair
Evaluation Conformal Radiotherapy for Gynecologic Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is comparision conformal radiotherapy for gynecologic cancer

Conditions
-----------------
Radiation Therapy

Intervention / Treatment
-----------------
* Radiation: conformal radiotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gynecologic cancer Exclusion Criteria: Metastases
Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Radiation: conformal radiotherapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Does Tracheal Tube Size Affect Patient's Experience of Postoperative Sore Throat and Hoarseness

Study Overview
=================
Brief Summary
-----------------
How tube size affect patient's experience of postoperative sore throat and hoarseness

Detailed Description
-----------------
A randomised controlled study studying how tube size affect patient's experience of postoperative sore throat and hoarseness. The patients are randomised on the basis of gender. Men are randomized to tube size 8.0 (usual) or 7.0. Women are randomized to tube size 7.0 (usual) or 6.0.

Official Title
-----------------
Does Tracheal Tube Size Affect Patient's Experience of Postoperative Sore Throat and Hoarseness

Conditions
-----------------
Sore Throat, Hoarseness

Intervention / Treatment
-----------------
* Device: Smaller tube size


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Need for intubation Elective surgery ASA Group I and II Understands and speaks Danish give one's consent Exclusion Criteria: Known dementia SARI score >4 BMI > 35 Acute intubation attempt intubation > 2 known with previously difficult intubation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Woman tube size 6.0<br>Smaller tube than normal | Device: Smaller tube size<br>* Comparing how tube size affect patient's experience of postoperative sore throat and hoarseness in men and women.<br>|
| No Intervention: Woman tube size 7.0<br>Usual tube size | |
| Experimental: Man tube size 7.0<br>Smaller tube than normal | Device: Smaller tube size<br>* Comparing how tube size affect patient's experience of postoperative sore throat and hoarseness in men and women.<br>|
| No Intervention: Man tube size 8.0<br>Usual tube size | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sore throat after intubation | Survey - experienced postoperative sore throat after intubation. A scale from 1-4 is used; 1 indicated no sore throat and 4 indicated seriously sore throat. | 7 days | 
| Hoarseness after intubation | Survey - experienced postoperative hoarseness after intubation. A scale from 1-4 is used; 1 indicated no hoarseness and 4 indicated seriously hoarseness. | 7 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
postoperative, Tube size, Patient experience
Ethically Accepted With Code 851/2971 A Comparison of Class Ⅱ Malocclusion Treatment Using Van Beek-headgear Activator Versus Andresen Activator

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to compare the treatment results when treating Class II division 1 malocclusion using the Van Beek-Headgear Activator combination (vBHGA) appliance versus using the Andresen activator.

Official Title
-----------------
A Comparison of Class Ⅱ Malocclusion Treatment Using Van Beek-headgear Activator Versus Andresen Activator: A Randomized Clinical Trial

Conditions
-----------------
Class II Growth Modification

Intervention / Treatment
-----------------
* Device: Van-Beek activator and a headgear
* Device: Andresen activator


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Class II division 1 indicated by ANB angle value ≥ 4º Class II division 1 with overjet > 5mm. An age range between 8 and 13 years growing patient using cervical vertebral stage assessment (CVS). No previous orthodontic treatment No indications or symptoms of periodontal disease in the past or present, as determined by clinical and radiographic examination Exclusion Criteria: Missing teeth (excluding 3rd molars). Craniofacial anomalies. Medical condition or prescription medication that may affect growth. Lack of compliance whenever documented in the charts.

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 13 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Group A<br>12 patients will receive Van-Beek activator and a headgear | Device: Van-Beek activator and a headgear<br>* 12 patients will receive Van-Beek activator and a headgear<br>|
| Active Comparator: Group B<br>12 patients will receive Andresen activator | Device: Andresen activator<br>* 12 patients will receive Andresen activator.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| treating Class II division 1 malocclusion | rate of mandibular and maxillary growth | at 8 months |
Topical Steroids and Cyclosporin-A for COVID-19 Keratoconjunctivitis

Study Overview
=================
Brief Summary
-----------------
To explore the feasibility of combined topical corticosteroid and topical cyclosporine-A in COVID-19 patients with acute keratoconjunctivitis.

Detailed Description
-----------------
COVID-19 patients presenting with acute keratoconjunctivitis will be treated with Topical 1% prednisolone acetate fourTimes daily for 7 days as initial treatment, non-preserved artificial tears four times daily and cyclosporin A 0.5% four times daily . Twelve patients with COVID-19 Keratoconjunctivitis will be enrolled in this open-label study. Symptoms and findings of the patients before and after treatment were recorded.

Official Title
-----------------
Combined Topical Corticosteroid and Topical Cyclosporine-A for Management of COVID-19 Keratoconjunctivitis; a Pilot Study

Conditions
-----------------
Keratonjunctivitis

Intervention / Treatment
-----------------
* Drug: topical steroids and cyclosporin-A


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: COVID-19 Patients with keratoconjunctivitis Exclusion Criteria: associated ocular pathology or disease other causes of keratoconjunctivitis for example allergic or herpetic
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: COVID-19 keratoconjunctivitis<br>cases will receive topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily . | Drug: topical steroids and cyclosporin-A<br>* All patient will be treated with Topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily .<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Symptom improvement | eye itching, foreign body sensation, tearing, redness in the eye and eyelid swelling | 10-15 days | 
| Signs improvement | conjunctival injection, discharge, presence of superficial punctate keratitis (SPK), pseudomembranes on tarsal conjunctiva | 10-15 days |
Ocular Surface Changes in Patients With Cystic Fibrosis

Study Overview
=================
Brief Summary
-----------------
Cystic fibrosis(CF) is an inherited disease affecting children, adolescents and young adults with dysfunction of secretory glands.It is caused by mutations in the protein-coding gene which function as the cystic fibrosis transmembrane regulator (CFTR), responsible for the secretion of chloride ions in epithelial cells, adenocytes, sweat gland cells, pancreatic ducts,alimentary and respiratory tracts and eye. Assessment of the relationship between the inflammatory processes and apoptosis in the eye in the course of cystic fibrosis will allow determination of immunological exponents which may facilitate diagnosis.

Detailed Description
-----------------
The aim: To assess the role of chosen parameters of immunological response in the induction of ocular changes in cystic fibrosis patients, particularly chosen chemokine concentrations in the tear fluid and analysis of chosen apoptotic markers expression on conjunctival epithelial cells.

Official Title
-----------------
Chosen Parameters of the Immune Response in the Origin of Ocular Changes in Patients With Cystic Fibrosis

Conditions
-----------------
Eye Manifestations

Intervention / Treatment
-----------------
* Procedure: impression cytology, obtain the tear fluid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male and female patients aged 3-25 with clinically definite diagnosis of cystic fibrosis all patients must give written consent for participation in the study at screening Exclusion Criteria: patients with a history of chronic disease of the immune system patients with the history of systemic diseases patients with the history chronic ocular diseases patients who have been treated with corticosteroids in the past 3 months prior to the screening visit

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: impression cytology, obtain the tear fluid|Vitamin A|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cystic fibrosis, eye, inflammation, apoptosis, C11+
Nutritional Status in Retroperitoneal Sarcoma.

Study Overview
=================
Brief Summary
-----------------
Prospective feasibility study of perioperative nutrition in patients affected by primary retroperitoneal sarcoma

Detailed Description
-----------------
Aim of our study was to investigate the feasibility of a prehabilitation policy to optimize protein energetic reserves in a group of patients affected by primary localized RPS, candidate to a multiple organ resection surgery, as well as the feasibility of a standardized nutritional postoperative caloric target and its adequacy.

Official Title
-----------------
Perioperative Nutritional and Hemodinamic Support in Retroperitoneal Sarcoma Patients. A Phase II Prospective Feasibility Study.

Conditions
-----------------
Retroperitoneal Sarcoma, Malnutrition

Intervention / Treatment
-----------------
* Dietary Supplement: Oral Nutritional Support


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - every patient with retroperitoneal sarcoma scheduled for surgery Exclusion Criteria: chronic renal failure diabetes mellitus emergency surgery physical status classification system ASA>3 any contraindication to arterial catheter in Femoral artery for PICCO hemodynamic monitoring

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Sequential Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Primary retroperitoneal sarcoma<br>All eligible patients are screened in preoperative phase, at least 30 days before surgery, for presence of protein energetic malnutrition (PEM). PEM is defined according to biochemical and physiological parameters (Table). 3 class of PEM are identified: no PEM, mild PEM and serious PEM. Different nutritional oral supplements are provided according to the degree of malnutrition. | Dietary Supplement: Oral Nutritional Support<br>* Preoperative oral nutritional support is provided according to malnutrition grade<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of Adherence to protocol | Rate of adherence to prescribed oral nutritional support | 15 days |
Differences in Coagulation Test Kits

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to assess the effect of Innovin® reagent on laboratory results when compared with the Thromborel® S.

Detailed Description
-----------------
Thromboplastins are the screening tests which are used in the diagnosis of acquired or inherited disorders of the coagulation system but still, alterations between various thromboplastin preparations in the measurements remains a problem.Blood samples are going to drawn from patients receiving and not receiving oral anticoagulant therapy (OAT) during their routine laboratory tests. Samples are subjected to analysis by using Thromborel® S and Innovin® reagents. Mean International Normalized Ratio (INR), prothrombin time and fibrinogen values are going to compared. To further study the importance of this phenomenon the cohort will be divided into three subgroups according to the INR values as Group I: Patients not receiving OAT, Group II: Patients under OAT and INR values in good therapeutic range and Group III: Patients under OAT and INR values over the therapeutic range.

Official Title
-----------------
The Effects of Different Reagents on Coagulation Tests: Innovin Versus Thromborel-S.

Conditions
-----------------
Effect of Different Reagents., Oral Anticoagulant Therapy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Routine control patients receiving and not receiving oral anticoagulant therapy Exclusion Criteria: Hemolytic and/or lipemic samples were excluded.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| oral anticoagulant<br>Patients receiving and not receiving oral anticoagulant therapy. | |
| INR Level<br>Group I: Patients not receiving OAT, Group II: Patients under OAT and INR values in good therapeutic range and Group III: Patients under OAT and INR values over the therapeutic range. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Thromboplastin, Prothrombin, Diagnostic Reagent Kits, International Normalized Ratio, Laboratory Tests.
Effects of Sevoflurane and Propofol on Light Flash Evoked Pupillometry

Study Overview
=================
Brief Summary
-----------------
Null hypothesis (HO): There will be no difference in pupillometry readings when using any of the maintenance anesthetic techniques within subjects. Alternate hypothesis (HA): Pupillometry readings will be affected by a change in the anesthetic technique

Detailed Description
-----------------
Postoperative visual loss resulting from a surgical procedure not performed on the eye is a devastating outcome for the patient and poorly understood by the medical community. It is potentially a preventable complication. Diminished blood supply to the optic nerve, affecting both the anterior or posterior portions of the optic nerve, is the most common cause of postoperative visual loss. Other, less common causes include occlusion of the retinal artery and vein, a retinal embolism and cortical blindness. The incidence of postoperative visual loss increases in patients undergoing cardiopulmonary bypass and prone spine surgery. Although the etiology of post-operative visual loss is unknown, it is thought to be multifactorial, and several potential risk factors have been identified, including degree of low blood pressure, preoperative hematocrit, external compression of the eye, amount of blood loss, prolonged duration of surgical time and increased pressure in the eye associated with positioning. To date studies have focused on the mechanism associated with the visual loss. We would like to focus on the feasibility of using a monitor which may signal loss of visual function intraoperatively.

Official Title
-----------------
Effects of Sevoflurane and Propofol on Light Flash Evoked Pupillometry.

Conditions
-----------------
Measurement of Pupil Diameter

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients between the ages of 18 and 70 years of age who are mentally capable of providing an informed consent and who are medically classified as ASA 1 or 2. Planned elective orthopedic extremity surgery in the supine position with the head in the neutral position. Exclusion Criteria: Failure to provide an informed consent Known history of eye disease which cannot be corrected with lenses Surgery lasting less than 45 minutes

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Healthy volunteers | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| We would like to focus on the feasibility of using a monitor which may signal loss of visual function intraoperatively. |  | 18 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pupillometry, Sevoflorane, Propofol
Hormonal and Metabolic Effects of Weight Loss

Study Overview
=================
Brief Summary
-----------------
The investigators here propose to evaluate the hormonal and metabolic effects of weight loss, including evaluation of changes in several tissues.

Official Title
-----------------
Hormonal and Metabolic Effects of Weight Loss

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Behavioral: lifestyle


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI > 27 kg/m2 (adults) Exclusion Criteria: pregnancy, breastfeeding patients with: heart failure impaired hepatic or renal function anaemia disturbed coagulation infection, malabsorption severe hypertension any other endocrine disorder

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: life style intervention<br> | Behavioral: lifestyle<br>* lifestyle intervention, including diet, physical activity and behavioral changes<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hormonal and metabolic changes during weight loss |  | 6 month |